Newark, CA (Press Release) – Teneobio, Inc., a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that it has re­ceived orphan drug desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA) for the treat­ment of multiple myeloma.

“New and better treat­ment options are needed for multiple myeloma. While there are a number of BCMA-targeting agents cur­rently in clin­i­cal devel­op­ment, TNB-383B, an anti-BCMAxCD3 cur­rently in Phase I, is a bispecific com­prised of a unique T-cell engager designed to maximize the thera­peutic window for this class of drugs,” said …

Derzeit laufen weltweit mehr als 300 klinische Studien, die Behandlungen für das multiple Myelom untersuchen und nach teilnehmenden Patienten suchen. Die meisten dieser Studien erforschen neue Myelomtherapien, die noch nicht für den Einsatz außerhalb klinischer Studien zugelassen sind, und viele dieser sogenannten "investigativen" Therapien haben das Potenzial, extrem effektiv zu sein.

Die Zahl neuer Behandlungen, die für das multiple Myelom entwickelt wer­den, ist so hoch wie nie zuvor und das weckt große Hoffnung in der Myelom-Gemeinschaft. In nur wenigen Jahren dürften eine Reihe neuer Medikamente für die Be­hand­lung des Myeloms zugelassen werden …

There cur­rently are more than 300 clin­i­cal trials ongoing around the world that are investigating treat­ments for multiple myeloma and looking for patient par­tic­i­pants. Most of these trials are exploring new myeloma ther­a­pies that have not yet been approved for use outside of clin­i­cal trials, and many of these “investigational” ther­a­pies, as they often are called, have the poten­tial to be extremely effective.

The number of new treat­ments under devel­op­ment for multiple myeloma is greater than it ever has been, and this creates tremendous hope in the myeloma com­munity. In just a …

Newark, CA (Press Release) – Teneobio, Inc. a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that the first patient has been dosed with TNB-383B in a Phase 1 clin­i­cal study to eval­u­ate the safety and tolerability of its dif­fer­en­ti­ated anti-BCMAxCD3, a bispecific anti­body that redirects T-cells to kill multiple myeloma cells with minimal cytokine release. Earlier this year, Teneobio’s affiliate TeneoOne, Inc. and AbbVie entered a strategic part­ner­ship, giving AbbVie the exclusive right to acquire TeneoOne post-Phase 1 studies and lead the sub­se­quent global devel­op­ment and …

Newark, CA (Press Release) – Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their inves­ti­ga­tional new drug appli­ca­tion (IND) for TNB-383B, a bispecific T-cell engaging anti­body for the treat­ment of multiple myeloma, was cleared for the initiation of Phase I clin­i­cal studies by the US Food and Drug Admin­istra­tion (FDA) on April 24th, 2019. The ongoing devel­op­ment of TNB-383B is being pursued in col­lab­o­ration with AbbVie, Inc.

TNB-383B is a fully human bispecific anti­body with two binding moieties for B-Cell Maturation Antigen (BCMA) on one arm and a unique anti-CD3 on …

North Chicago, IL and Menlo Park, CA (Press Release) – AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic trans­­action to develop and com­mer­cial­ize TNB-383B, a BCMA-targeting immuno­therapeutic for the poten­tial treat­ment of multiple myeloma.

B-cell maturation an­ti­gen (BCMA) has emerged as an attractive target for multiple myeloma thera­peutics. TNB-383B is a bispecific anti­body that simultaneously targets BCMA and CD3, utilizing Teneobio's unique anti-CD3 plat­form. Through this dual targeting mech­a­nism, TNB-383B is designed to direct the body's own immune system to target and …